Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PRT037
MIFTS: 68

Pertussis

Categories: Infectious diseases, Rare diseases, Respiratory diseases, Smell/Taste diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pertussis

About this section

MalaCards integrated aliases for Pertussis:

Name: Pertussis 12 76 53 59 3 3 15 73
Whooping Cough 12 76 53 59 43 3 15
Bordetella Infections 44 73
Whooping Cough Due to Unspecified Organism 73
Bordetella Pertussis Infection 53
Bordetella Infection 12
Wc - Whooping Cough 12

Characteristics:

Orphanet epidemiological data:

59
whooping cough
Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
Anatomical: Respiratory diseases Smell/Taste diseases
See all MalaCards categories (disease lists)
ICD10: 34 33
Orphanet: 59  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:1116
MeSH 44 D001885
SNOMED-CT 68 26484003
Orphanet 59 ORPHA1489
MESH via Orphanet 45 D014917
UMLS via Orphanet 74 C0043167 C0043168
ICD10 via Orphanet 34 A37.0 A37.1 A37.8 more
Sources

Summaries for Pertussis

About this section
MedlinePlus : 43 Whooping cough is an infectious bacterial disease that causes uncontrollable coughing. The name comes from the noise you make when you take a breath after you cough. You may have choking spells or may cough so hard that you vomit. Anyone can get whooping cough, but it is more common in infants and children. It's especially dangerous for infants. The coughing spells can be so bad that it is hard for infants to eat, drink, or breathe. To make a diagnosis, your doctor may do a physical exam, blood tests, chest x-rays, or nose or throat cultures. Before there was a vaccine, whooping cough was one of the most common childhood diseases and a major cause of childhood deaths in the U.S. Now most cases are prevented by vaccines. If you have whooping cough, treatment with antibiotics may help if given early. Centers for Disease Control and Prevention

MalaCards based summary : Pertussis, also known as whooping cough, is related to neutrophil migration and pneumonia, and has symptoms including fever, pruritus and snoring. An important gene associated with Pertussis is TLR4 (Toll Like Receptor 4), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Montelukast and Edetic Acid have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and neutrophil, and related phenotypes are homeostasis/metabolism and hematopoietic system

Disease Ontology : 12 A commensal bacterial infectious disease that results in inflammation located in respiratory tract, has material basis in Bordetella pertussis, or has material basis in Bordetella parapertussis, which produce toxins that paralyze the cilia of the respiratory epithelial cells. The infection is characterized by a prolonged, high-pitched, deeply indrawn breath (whoop).

CDC : 3 Pronounced (per-TUS-iss)

Wikipedia : 76 Whooping cough (also known as pertussis or 100-day cough) is a highly contagious bacterial disease.... more...

Sources

Related Diseases for Pertussis

About this section

Diseases related to Pertussis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 327)
# Related Disease Score Top Affiliating Genes
1 neutrophil migration 30.3 ITGAM ITGB2 MAPK1
2 pneumonia 30.2 TNF TLR4 IL6 IL1B IL10
3 typhoid fever 30.1 TNF TLR4 IL6 IL1B
4 legionellosis 30.1 IL1B TLR4 TNF
5 sudden infant death syndrome 30.0 IL10 IL1B IL6 TNF
6 viral infectious disease 30.0 IL10 IL1B IL6 TNF
7 bronchiolitis 29.9 IL10 IL6 TLR4 TNF
8 peritonitis 29.9 TNF ITGAM IL6 IL1B IL10
9 meningitis 29.9 IL10 IL1B IL6 TNF
10 chlamydia 29.7 TNF TLR4 IL6 IL1B IL10
11 laryngitis 29.7 IL1B IL6 TNF
12 transverse myelitis 29.7 IL10 IL6 TNF
13 perinatal necrotizing enterocolitis 29.6 TNF TLR4 IL6 IL1B
14 chorioamnionitis 29.6 TNF TLR4 IL6 IL1B
15 brucellosis 29.6 TNF TLR4 IL6 IL10
16 cytomegalovirus infection 29.6 IL1B IL6 TNF
17 myocarditis 29.6 IL6 ITGB2 TNF
18 contact dermatitis 29.5 IL10 IL1B IL6 TNF
19 asthma 29.5 IL10 IL1B IL6 ITGAM TLR4 TNF
20 q fever 29.5 TNF TLR4 IL6 IL1B IL10
21 kawasaki disease 29.5 IL10 IL6 TNF
22 colitis 29.5 TNF TLR4 IL6 IL1B IL10
23 inflammatory bowel disease 29.4 IL10 IL1B IL6 JUN TLR4 TNF
24 monocytic leukemia 29.4 TNF JUN ITGAM IL6 IL1B
25 myocardial infarction 29.2 IL10 IL1B IL6 ITGAM TLR4 TNF
26 diphtheria 11.6
27 bordetella parapertussis whooping cough 11.1
28 tetanus 11.0
29 haemophilus influenzae 10.6
30 hepatitis 10.6
31 hepatitis b 10.5
32 influenza 10.5
33 poliomyelitis 10.5
34 scarlet fever 10.4
35 measles 10.3
36 cholera 10.3
37 smallpox 10.3
38 rickets 10.3
39 punctate inner choroidopathy 10.2 IL10 TNF
40 campylobacteriosis 10.2 IL1B JUN TLR4
41 prosthetic joint infection 10.2 IL1B TLR4
42 exudative glomerulonephritis 10.2 IL1B TNF
43 tropical endomyocardial fibrosis 10.2 IL10 TNF
44 mumps 10.2
45 salmonellosis 10.2 IL1B JUN TLR4
46 scorpion envenomation 10.2 IL6 TNF
47 bacterial sepsis 10.2 IL10 TLR4 TNF
48 cysticercosis 10.2 IL1B IL6 TLR4
49 cystic echinococcosis 10.2 IL10 IL6 TLR4
50 hand, foot and mouth disease 10.2 IL10 IL6 TLR4

Graphical network of the top 20 diseases related to Pertussis:



Diseases related to Pertussis
Sources

Symptoms & Phenotypes for Pertussis

About this section

UMLS symptoms related to Pertussis:


fever, pruritus, snoring, coughing

MGI Mouse Phenotypes related to Pertussis:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.4 FOS GNAI1 GNAQ GNAZ IL10 IL1B
2 hematopoietic system MP:0005397 10.39 FOS GNAI1 GNAQ GNAZ IL10 IL1B
3 behavior/neurological MP:0005386 10.37 FOS GNAI1 GNAQ GNAZ IL10 IL6
4 cardiovascular system MP:0005385 10.33 GNAQ IL10 IL1B IL6 ITGB2 JUN
5 immune system MP:0005387 10.32 FOS GNAI1 GNAQ IL10 IL1B IL6
6 cellular MP:0005384 10.28 FOS IL10 IL6 ITGAM ITGB2 JUN
7 mortality/aging MP:0010768 10.25 FOS GNAQ GNAZ IL10 IL1B IL6
8 integument MP:0010771 10.23 FOS GNAQ GNAZ IL10 IL1B IL6
9 nervous system MP:0003631 10.21 FOS GNAI1 GNAQ GNAZ IL10 IL1B
10 endocrine/exocrine gland MP:0005379 10.18 FOS GNAQ IL10 IL6 JUN MAPK1
11 normal MP:0002873 10.02 FOS GNA15 GNAQ IL10 ITGB2 JUN
12 neoplasm MP:0002006 9.95 FOS IL10 IL1B IL6 MAPK1 TLR4
13 reproductive system MP:0005389 9.91 FOS GNAZ IL10 IL6 MAPK1 OPRM1
14 respiratory system MP:0005388 9.76 GNAQ IL10 IL6 JUN MAPK1 TLR4
15 skeleton MP:0005390 9.7 FOS GNAI1 GNAQ IL10 IL1B IL6
16 vision/eye MP:0005391 9.28 FOS IL10 IL6 ITGB2 JUN MAPK1
Sources

Drugs & Therapeutics for Pertussis

About this section

Drugs for Pertussis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Montelukast Approved Phase 4 158966-92-8 5281040
2
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 62-33-9, 60-00-4 6049
3
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
4
Pentetic acid Approved Phase 4,Phase 3,Phase 2 67-43-6
5
Ibuprofen Approved Phase 4,Phase 2 15687-27-1 3672
6
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
7
BCG vaccine Investigational Phase 4,Phase 2
8 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
9 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
10 Adjuvants, Immunologic Phase 4,Phase 3,Phase 1,Phase 2
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
12 Hormones Phase 4,Phase 3
13 Respiratory System Agents Phase 4
14 Hormone Antagonists Phase 4,Phase 3
15 Anti-Asthmatic Agents Phase 4
16 Leukotriene Antagonists Phase 4
17 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
19 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2
22 Antacids Phase 4,Phase 3,Phase 2
23 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
24 Aluminum phosphate Phase 4,Phase 3,Phase 1,Phase 2
25 Antidotes Phase 4,Phase 3,Phase 2
26 Diphtheria Antitoxin Phase 4,Phase 3
27 Tetanus Antitoxin Phase 4,Phase 3
28 Antitoxins Phase 4,Phase 3
29 Anticoagulants Phase 4,Phase 3,Phase 2
30 Chelating Agents Phase 4,Phase 3,Phase 2
31 Iron Chelating Agents Phase 4,Phase 3,Phase 2
32 Calcium, Dietary Phase 4,Phase 3,Phase 2
33 PENTA Phase 4,Phase 3,Phase 2,Not Applicable
34 Fibrinolytic Agents Phase 4,Phase 3,Phase 2
35 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
36 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
38 Cyclooxygenase Inhibitors Phase 4,Phase 2
39 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
40 Antirheumatic Agents Phase 4,Phase 2
41 Antipyretics Phase 4,Phase 3
42 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
43
Deferiprone Approved Phase 3 30652-11-0 2972
44
Aluminum hydroxide Approved, Investigational Phase 3,Phase 2 21645-51-2
45
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
46
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
47
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
48
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
49
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
50
Lactitol Investigational Phase 3,Phase 2 585-86-4 3871

Interventional clinical trials:

(show top 50) (show all 502)
# Name Status NCT ID Phase Drugs
1 Pertussis (Tdap) Vaccination in Pregnancy Unknown status NCT01698346 Phase 4
2 Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand Unknown status NCT02408926 Phase 4
3 Diphtheria, Tetanus, Poliomyelitis -Pertussis-Hib Immunisation in Preterm-born Neonates Unknown status NCT02179996 Phase 4
4 The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients Unknown status NCT00336115 Phase 4
5 Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
6 An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster Unknown status NCT00870350 Phase 4
7 Influence of BCG on TDaP-IPV Vaccination Unknown status NCT02771782 Phase 4
8 Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine Unknown status NCT00877357 Phase 4
9 Montelukast for Persistent Cough in Young People and Adults Unknown status NCT01279668 Phase 4 Montelukast;Placebo
10 Pertussis and Meningitis C Concomitant Vaccination in Adolescents Completed NCT02526394 Phase 4 Pertussis containing vaccine
11 A Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants Completed NCT02145624 Phase 4 Repevax;Boostrix-IPV
12 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine Completed NCT00304265 Phase 4
13 Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose Completed NCT00712959 Phase 4
14 Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine Completed NCT00514059 Phase 4 Boostrix polio
15 Immunogenicity and Safety of Concomitant Administration of RotaTeqâ„¢ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) Completed NCT01926015 Phase 4
16 Study of Adacel® Vaccine Administered to Persons 10 Years of Age Completed NCT01311557 Phase 4
17 Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants Completed NCT02907216 Phase 4
18 Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine Completed NCT00347958 Phase 4
19 A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older Completed NCT00457249 Phase 4
20 Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine Completed NCT00674908 Phase 4
21 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
22 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Completed NCT01439165 Phase 4
23 Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX® Completed NCT00319553 Phase 4
24 Regulatory Post-Marketing Surveillance Study for TETRAXIMâ„¢ Completed NCT01437423 Phase 4
25 Tdap Vaccine in Post-Partum Women Completed NCT01711645 Phase 4
26 Post Marketing Surveillance for ADACELâ„¢ in South Korea Completed NCT01137435 Phase 4
27 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Completed NCT01629589 Phase 4
28 Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women Completed NCT02783170 Phase 4
29 A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants. Completed NCT01250756 Phase 4
30 Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACELâ„¢ Completed NCT00802867 Phase 4
31 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
32 Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination Completed NCT00244673 Phase 4
33 US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease Completed NCT00282295 Phase 4
34 Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068) Completed NCT00289913 Phase 4
35 Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine Completed NCT00617812 Phase 4
36 Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine Completed NCT00777257 Phase 4
37 Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination Completed NCT01357720 Phase 4
38 Assessment of the Immunogenicity and Safety of PENTAXIMâ„¢ in Philippines Completed NCT00254917 Phase 4
39 Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrixâ„¢ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
40 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
41 Tropical Influenza Control Strategies for the Elderly Completed NCT02655874 Phase 4
42 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. Completed NCT00610168 Phase 4
43 Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults Completed NCT01323959 Phase 4
44 Immunogenicity and Safety of TETRAXIMâ„¢ Given as a Booster Dose at 4 to 6 Years of Age Completed NCT01031303 Phase 4
45 Immunology of Non-specific Effects of Vaccine Completed NCT00168545 Phase 4
46 Evaluation of Boostrixâ„¢10 Years After Previous Booster Vaccination Completed NCT01147900 Phase 4
47 Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents Completed NCT01362322 Phase 4
48 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrixâ„¢ Vaccine in Pregnant Women Completed NCT02377349 Phase 4 Saline placebo
49 Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
50 Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) Completed NCT01294605 Phase 4

Search NIH Clinical Center for Pertussis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: bordetella infections

Sources

Genetic Tests for Pertussis

About this section
Sources

Anatomical Context for Pertussis

About this section

MalaCards organs/tissues related to Pertussis:

41
Testes, T Cells, Neutrophil, Lung, Monocytes, Brain, Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Pertussis:

19
Respiratory Tract
Sources

Publications for Pertussis

About this section

Articles related to Pertussis:

(show top 50) (show all 2971)
# Title Authors Year
1
Observational studies of non-specific effects of Diphtheria-Tetanus-Pertussis vaccines in low-income countries: Assessing the potential impact of study characteristics, bias and confounding through meta-regression. ( 30471957 )
2019
2
Seroprevalence of pertussis among healthcare workers: A cross-sectional study from Tunisia. ( 30459070 )
2019
3
Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro. ( 30478007 )
2019
4
Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3. ( 29433898 )
2018
5
Seroepidemiology of diphtheria and pertussis in Chongqing, China: serology-based evidence of Bordetella pertussis infection. ( 29408190 )
2018
6
Pertussis vaccination in a cohort of older Australian adults following a cocooning vaccination program. ( 29887324 )
2018
7
Myocarditis following diphtheria, whole-cell pertussis, and tetanus toxoid vaccination in a young infant. ( 29922028 )
2018
8
Risk factors for pertussis among hospitalized children in a high HIV prevalence setting, South Africa. ( 29410230 )
2018
9
A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults. ( 29172945 )
2018
10
Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents. ( 29862604 )
2018
11
Molecular and cellular signatures underlying superior immunity against Bordetella pertussis upon pulmonary vaccination. ( 29411776 )
2018
12
Effectiveness of acellular pertussis vaccine and evolution of pertussis incidence in the community of Madrid from 1998 to 2015. ( 29439872 )
2018
13
Effectiveness of Prenatal Tetanus, Diphtheria, Acellular Pertussis Vaccination in the Prevention of Infant Pertussis in the U.S. ( 29910115 )
2018
14
On the Role of Different Age Groups and Pertussis Vaccines During the 2012 Outbreak in Wisconsin. ( 29942818 )
2018
15
Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose. ( 29438562 )
2018
16
A quality improvement initiative to increase Tdap (tetanus, diphtheria, acellular pertussis) vaccination coverage among direct health care providers at a children's hospital. ( 29217370 )
2018
17
Pharmacists' Attitudes and Practices Regarding Tetanus, Diphtheria and Pertussis (Tdap) Vaccination in Pregnancy and Surrounding Newborns. ( 29693570 )
2018
18
Pertussis: New preventive strategies for an old disease. ( 29914744 )
2018
19
The importance of involving midwives before and during the implementation of an antenatal pertussis vaccination program in New South Wales, Australia. ( 29398459 )
2018
20
An ELISA method to estimate the mono ADP-ribosyltransferase activities: e.g in pertussis toxin and vaccines. ( 29108883 )
2018
21
A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial. ( 29066131 )
2018
22
Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children. ( 29391374 )
2018
23
A rapid lateral flow immunoassay for serological diagnosis of pertussis. ( 29426656 )
2018
24
Nucleobase modified adefovir (PMEA) analogues as potent and selective inhibitors of adenylate cyclases from Bordetella pertussis and Bacillus anthracis. ( 29968968 )
2018
25
Safer Pertussis Vaccines for Children: Trading Efficacy for Safety. ( 29866796 )
2018
26
Whole-Cell or Acellular Pertussis Primary Immunizations in Infancy Determines Adolescent Cellular Immune Profiles. ( 29416544 )
2018
27
Assessing the reactogenicity of Tdap vaccine administered during pregnancy and antibodies to Bordetella pertussis antigens in maternal and cord sera of Thai women. ( 29426663 )
2018
28
Cognitive Development One Year After Infantile Critical Pertussis. ( 29394223 )
2018
29
Pneumococcal Immune Response in Infants Whose Mothers Received Tetanus, Diphtheria and Acellular Pertussis Vaccination During Pregnancy: ERRATUM. ( 29652740 )
2018
30
Outbreak investigation of pertussis in an elementary school: a case-control study among vaccinated students. ( 29399582 )
2018
31
Response to: Bordetella Pertussis in hajj pilgrims. ( 29449052 )
2018
32
Patient attitudes toward influenza and tetanus, diphtheria and acellular pertussis vaccination in pregnancy. ( 29907484 )
2018
33
Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters. ( 29920186 )
2018
34
A General Lack of IgG Against Pertussis Toxin in Chinese Pregnant Women and Newborns. ( 29406469 )
2018
35
<i>Bordetella Pertussis</i> Adenylate Cyclase Toxin Does Not Possess a Phospholipase A Activity; Serine 606 and Aspartate 1079 Residues Are Not Involved in Target Cell Delivery of the Adenylyl Cyclase Enzyme Domain. ( 29914160 )
2018
36
Relationship between patient copayments in Medicare Part D and vaccination claim status for herpes zoster and tetanus-diphtheria-acellular pertussis. ( 29231748 )
2018
37
Immunization of preterms with hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: The position of the Italian Pediatric Society. ( 29880242 )
2018
38
Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study. ( 29960800 )
2018
39
Factors associated with uptake of influenza and pertussis vaccines among pregnant women in South Australia. ( 29902184 )
2018
40
Lichen planus following tetanus-diphtheria-acellular pertussis vaccination: A case report and review of the literature. ( 29326823 )
2018
41
Virulence Associated Gene 8 of <i>Bordetella pertussis</i> Enhances Contact System Activity by Inhibiting the Regulatory Function of Complement Regulator C1 Inhibitor. ( 29915576 )
2018
42
Core pertussis transmission groups in England and Wales: A tale of two eras. ( 29395520 )
2018
43
Tdap vaccination during pregnancy to protect newborns from pertussis infection. ( 29895052 )
2018
44
Bordetella Pertussis in hajj pilgrims. ( 29395635 )
2018
45
Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). ( 29702631 )
2018
46
Extracorporeal Membrane Oxygenation for Pertussis: Predictors of Outcome Including Pulmonary Hypertension and Leukodepletion. ( 29319632 )
2018
47
Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. ( 29336924 )
2018
48
Predictors of pertussis outbreak in urban and rural municipalities of Saskatchewan, Canada. ( 29981084 )
2018
49
The pertussis hypothesis: Bordetella pertussis colonization in the etiology of asthma and diseases of allergic sensitization. ( 30220328 )
2018
50
Chlamydia trachomatis, Bordetella pertussis and other respiratory bacteria in the aetiology of lower respiratory tract infections in young infants. ( 30160339 )
2018
Sources

Variations for Pertussis

About this section
Sources

Expression for Pertussis

About this section
Search GEO for disease gene expression data for Pertussis.
Sources

Pathways for Pertussis

About this section

Pathways related to Pertussis according to GeneCards Suite gene sharing:

(show top 50) (show all 217)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 14.21 CALM1 FOS IL10 IL1B IL6 ITGAM
2
Apoptotic Pathways in Synovial Fibroblasts 64
Show member pathways
 14.05 FOS GNA14 GNA15 GNAI1 GNAQ GNAZ
3
ERK Signaling 64
Show member pathways
 14.04 FOS GNA14 GNA15 GNAI1 GNAZ IL10
4
GPCR Pathway 64
Show member pathways
 13.91 CALM1 FOS GNA14 GNA15 GNAI1 GNAZ
5
PEDF Induced Signaling 64
Show member pathways
 13.84 CALM1 FOS GNA14 GNA15 GNAI1 GNAZ
6
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 66
Show member pathways
 13.73 CALM1 GNAI1 GNAQ IL1B IL6 JUN
7
TGF-Beta Pathway 64
Show member pathways
 13.71 CALM1 FOS GNA14 GNA15 IL10 IL1B
8
Integrin Pathway 64
Show member pathways
 13.6 CALM1 FOS GNA14 GNA15 GNAI1 GNAZ
9
Cytokine Signaling in Immune system 66
Show member pathways
 13.56 CALM1 FOS IL10 IL1B IL6 ITGAM
10
Akt Signaling 64
Show member pathways
 13.55 FOS GNA14 GNA15 GNAI1 GNAZ IL10
11
Response to elevated platelet cytosolic Ca2+ 66
Show member pathways
 13.51 CALM1 GNA14 GNA15 GNAI1 GNAQ ITGAM
12
PAK Pathway 64
Show member pathways
 13.48 FOS IL10 IL1B IL6 JUN MAPK1
13
CREB Pathway 64
Show member pathways
 13.47 CALM1 GNA14 GNA15 GNAI1 GNAZ IL6
14
Nanog in Mammalian ESC Pluripotency 64
Show member pathways
 13.46 CALM1 FOS GNAI1 IL6 JUN MAPK1
15
IL-2 Pathway 64
Show member pathways
 13.42 CALM1 FOS GNAI1 GNAQ GNAZ IL1B
16
DAG and IP3 signaling 66
Show member pathways
 13.3 CALM1 GNA14 GNA15 GNAI1 GNAQ GNAZ
17
Phospholipase-C Pathway 64
Show member pathways
 13.28 CALM1 GNA14 GNA15 GNAI1 GNAZ IL6
18
Sweet Taste Signaling 64
Show member pathways
 13.28 CALM1 FOS GNA14 GNA15 GNAI1 GNAZ
19
p70S6K Signaling 64
Show member pathways
 13.26 FOS GNA14 GNA15 GNAI1 IL6 JUN
20
Circadian entrainment 37
Show member pathways
 13.25 CALM1 FOS GNA15 GNAI1 GNAQ JUN
21
G-Beta Gamma Signaling 64
Show member pathways
 13.24 CALM1 FOS GNA14 GNA15 GNAI1 GNAZ
22
Human cytomegalovirus infection 37
Show member pathways
 13.23 CALM1 FOS GNAI1 GNAQ IL1B IL6
23
fMLP Pathway 64
Show member pathways
 13.22 CALM1 FOS GNA14 GNA15 GNAI1 GNAQ
24
Actin Nucleation by ARP-WASP Complex 64
Show member pathways
 13.19 CALM1 FOS GNA14 GNA15 GNAI1 GNAZ
25
TNFR1 Pathway 64
Show member pathways
 13.18 CALM1 FOS GNAI1 GNAQ GNAZ IL6
26
Development Angiotensin activation of ERK 22
Show member pathways
 13.13 CALM1 FOS GNAI1 GNAQ GNAZ ITGB2
27
Sertoli-Sertoli Cell Junction Dynamics 64
Show member pathways
 13.12 FOS ITGAM ITGB2 JUN MAPK1 MAPK10
28
Toll-like Receptor Signaling Pathway 37 1
Show member pathways
 13.12 FOS GNA14 GNA15 GNAI1 GNAQ IL10
29
CCR5 Pathway in Macrophages 64
Show member pathways
 13.11 CALM1 FOS GNA14 GNA15 GNAI1 JUN
30
Allograft rejection 1 37
Show member pathways
 13.1 CALM1 FOS IL10 IL1B IL6 ITGB2
31
Focal Adhesion 1 37
Show member pathways
 13.07 FOS ITGAM ITGB2 JUN MAPK1 MAPK10
32
Pathways in cancer 37
13.06 CALM1 FOS GNAI1 GNAQ IL6 JUN
33
NFAT and Cardiac Hypertrophy 64
Show member pathways
 13.06 CALM1 GNA14 GNA15 GNAI1 IL6 ITGAM
34
Influenza A 37
Show member pathways
 13.02 FOS IL1B IL6 JUN MAPK1 MAPK10
35
MAPK-Erk Pathway 67
Show member pathways
 13 CALM1 FOS GNAI1 ITGAM ITGB2 MAPK1
36
Glioma 37
Show member pathways
 12.96 CALM1 FOS IL6 JUN MAPK1 MAPK10
37
Beta-Adrenergic Signaling 64
Show member pathways
 12.96 FOS GNA14 GNA15 GNAI1 GNAZ ITGAM
38
MAPK signaling pathway 37 1
12.95 FOS IL1B JUN MAPK1 MAPK10 TNF
39
Ras signaling pathway 37
Show member pathways
 12.95 CALM1 GNAI1 GNAQ ITGAM ITGB2 MAPK1
40
Apoptosis Modulation and Signaling 1
Show member pathways
 12.94 FOS JUN MAPK1 MAPK10 TNF
41
Vascular smooth muscle contraction 37
Show member pathways
 12.92 CALM1 FOS GNAI1 GNAQ JUN MAPK1
42
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 65
Show member pathways
 12.91 FOS IL6 JUN MAPK1 TNF
43
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways 66
Show member pathways
 12.9 IL1B IL6 MAPK10 TLR4 TNF
44
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.88 CALM1 FOS GNAI1 GNAQ GNAZ IL1B
45
4-1BB Pathway 64
Show member pathways
 12.87 FOS IL1B JUN MAPK1 MAPK10 TNF
46
Immune response NFAT in immune response 22
Show member pathways
 12.87 CALM1 FOS GNA15 IL10 JUN MAPK1
47
Development HGF signaling pathway 22
Show member pathways
 12.86 CALM1 FOS JUN MAPK1 MAPK10
48
G-AlphaQ Signaling 64
Show member pathways
 12.86 CALM1 GNA14 GNA15 GNAI1 GNAZ MAPK1
49
NF-KappaB Family Pathway 64
Show member pathways
 12.85 CALM1 IL1B IL6 TLR4 TNF
50
TRAF Pathway 64
Show member pathways
 12.83 CALM1 FOS GNAQ IL1B JUN MAPK1
Sources

GO Terms for Pertussis

About this section

Cellular components related to Pertussis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.35 GNAI1 ITGAM ITGB2 OPRM1 TNF
2 transcription factor AP-1 complex GO:0035976 9.26 FOS JUN
3 integrin alphaM-beta2 complex GO:0034688 9.16 ITGAM ITGB2
4 heterotrimeric G-protein complex GO:0005834 9.02 GNA14 GNA15 GNAI1 GNAQ GNAZ
5 plasma membrane GO:0005886 10.13 CALM1 GNA14 GNA15 GNAI1 GNAQ GNAZ

Biological processes related to Pertussis according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Name GO ID Score Top Affiliating Genes
1 aging GO:0007568 9.97 FOS IL10 ITGB2 JUN SERPING1
2 positive regulation of DNA-binding transcription factor activity GO:0051091 9.95 IL10 IL1B IL6 TNF
3 cellular response to lipopolysaccharide GO:0071222 9.93 IL10 IL1B IL6 TLR4 TNF
4 positive regulation of JNK cascade GO:0046330 9.92 IL1B TLR4 TNF
5 positive regulation of endothelial cell proliferation GO:0001938 9.91 IL10 JUN VIP
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.91 IL1B IL6 ITGB2 TLR4 TNF
7 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.89 GNAI1 GNAZ OPRM1
8 positive regulation of smooth muscle cell proliferation GO:0048661 9.88 IL6 JUN TNF
9 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.88 IL1B TLR4 TNF
10 Fc-epsilon receptor signaling pathway GO:0038095 9.88 CALM1 FOS JUN MAPK1 MAPK10
11 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.87 IL10 JUN TNF
12 positive regulation of interferon-gamma production GO:0032729 9.87 IL1B TLR4 TNF
13 cellular response to organic substance GO:0071310 9.87 IL1B MAPK1 MAPK10
14 inflammatory response GO:0006954 9.87 FOS IL10 IL1B IL6 ITGB2 TLR4
15 response to glucocorticoid GO:0051384 9.86 IL10 IL1B IL6 TNF
16 cellular response to cadmium ion GO:0071276 9.85 FOS JUN MAPK1
17 positive regulation of neuron death GO:1901216 9.85 FOS ITGAM ITGB2
18 activation of MAPK activity GO:0000187 9.85 IL1B MAPK1 MAPK10 TLR4 TNF
19 cellular response to reactive oxygen species GO:0034614 9.84 FOS JUN MAPK1
20 regulation of sensory perception of pain GO:0051930 9.83 IL10 OPRM1 VIP
21 positive regulation of interleukin-6 production GO:0032755 9.83 IL1B IL6 TLR4 TNF
22 platelet activation GO:0030168 9.83 GNA14 GNA15 GNAQ IL6 MAPK1
23 negative regulation of interleukin-6 production GO:0032715 9.82 IL10 TLR4 TNF
24 positive regulation of interleukin-8 production GO:0032757 9.81 IL1B TLR4 TNF
25 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.81 FOS IL10 JUN
26 positive regulation of nitric oxide biosynthetic process GO:0045429 9.8 IL1B ITGB2 TLR4 TNF
27 negative regulation of neurogenesis GO:0050768 9.79 IL1B IL6 TNF
28 regulation of DNA-binding transcription factor activity GO:0051090 9.79 FOS JUN MAPK1
29 positive regulation of chemokine production GO:0032722 9.78 IL6 TLR4 TNF
30 positive regulation of glial cell proliferation GO:0060252 9.77 IL1B IL6 TNF
31 toll-like receptor 4 signaling pathway GO:0034142 9.76 ITGAM ITGB2 TLR4
32 amyloid-beta clearance GO:0097242 9.74 ITGAM ITGB2
33 cell-cell adhesion via plasma-membrane adhesion molecules GO:0098742 9.74 ITGAM ITGB2
34 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.74 TLR4 TNF
35 negative regulation of lipid storage GO:0010888 9.73 IL6 TNF
36 negative regulation of synaptic transmission GO:0050805 9.73 GNAI1 IL1B
37 positive regulation of microglial cell activation GO:1903980 9.73 ITGAM ITGB2
38 endothelial cell apoptotic process GO:0072577 9.73 IL10 TNF
39 positive regulation of chemokine biosynthetic process GO:0045080 9.72 IL1B TNF
40 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.72 IL10 IL1B TNF
41 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.71 GNA14 GNA15
42 positive regulation of MHC class II biosynthetic process GO:0045348 9.71 IL10 TLR4
43 regulation of establishment of endothelial barrier GO:1903140 9.71 IL1B TNF
44 lipopolysaccharide-mediated signaling pathway GO:0031663 9.71 IL1B MAPK1 TLR4 TNF
45 negative regulation of cytokine secretion involved in immune response GO:0002740 9.7 IL10 TNF
46 positive regulation of fever generation GO:0031622 9.7 IL1B TNF
47 cellular extravasation GO:0045123 9.69 ITGB2 TNF
48 chronic inflammatory response to antigenic stimulus GO:0002439 9.68 IL1B TNF
49 negative regulation of dopamine metabolic process GO:0045963 9.68 ITGAM ITGB2
50 positive regulation of neutrophil degranulation GO:0043315 9.68 ITGAM ITGB2

Molecular functions related to Pertussis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.88 FOS ITGAM ITGB2 JUN TLR4
2 GTP binding GO:0005525 9.83 GNA14 GNA15 GNAI1 GNAQ GNAZ
3 cytokine activity GO:0005125 9.76 IL10 IL1B IL6 TNF
4 GTPase activity GO:0003924 9.72 GNA14 GNA15 GNAI1 GNAQ GNAZ
5 G protein-coupled receptor binding GO:0001664 9.55 GNA14 GNA15 GNAI1 GNAQ GNAZ
6 complement component C3b binding GO:0001851 9.4 ITGAM ITGB2
7 G protein-coupled serotonin receptor binding GO:0031821 9.37 GNAI1 GNAZ
8 G-protein beta/gamma-subunit complex binding GO:0031683 9.35 GNA14 GNA15 GNAI1 GNAQ GNAZ
9 guanyl nucleotide binding GO:0019001 9.02 GNA14 GNA15 GNAI1 GNAQ GNAZ
10 protein binding GO:0005515 10.23 CALM1 FOS GNA14 GNAI1 GNAQ GNAZ
Sources

Sources for Pertussis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....